Cargando…

Nasal transmission of equine parvovirus hepatitis

BACKGROUND: Equine parvovirus hepatitis (EqPV‐H) is highly prevalent and causes subclinical to fatal hepatitis, which can occur in outbreaks. Whereas iatrogenic transmission is well documented, the mode of horizontal transmission is not known. The virus is shed in nasal, oral and fecal secretions, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomlinson, Joy E., Van de Walle, Gerlinde R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708389/
https://www.ncbi.nlm.nih.gov/pubmed/36250682
http://dx.doi.org/10.1111/jvim.16569
_version_ 1784840920657559552
author Tomlinson, Joy E.
Van de Walle, Gerlinde R.
author_facet Tomlinson, Joy E.
Van de Walle, Gerlinde R.
author_sort Tomlinson, Joy E.
collection PubMed
description BACKGROUND: Equine parvovirus hepatitis (EqPV‐H) is highly prevalent and causes subclinical to fatal hepatitis, which can occur in outbreaks. Whereas iatrogenic transmission is well documented, the mode of horizontal transmission is not known. The virus is shed in nasal, oral and fecal secretions, and PO transmission has been reported in a single horse. HYPOTHESIS/OBJECTIVE: Investigate the efficiency of PO and nasal transmission of EqPV‐H in a larger cohort. METHODS: Prospective experimental transmission study. Eleven EqPV‐H‐negative horses were inoculated with 5 × 10(6) genome equivalents EqPV‐H. Serum PCR and serology for EqPV‐H were performed weekly and monthly, respectively. Horses first were inoculated PO, and then intranasally 8 weeks later. RESULTS: No horse became viremic or seroconverted within 8 weeks after PO inoculation. After intranasal inoculation, 5 horses became viremic within 6 to 12 weeks and seroconverted within 10 to 19 weeks. After a period without monitoring from 12 to 19 weeks postinoculation, another 5 horses were found to be viremic at 19 to 22 weeks. The second set of 5 horses could have been infected by horizontal transmission from the first 5 because of cohousing. CONCLUSIONS AND CLINICAL IMPORTANCE: We demonstrated that EqPV‐H can be transmitted nasally. The prolonged eclipse phase before detectable viremia indicates biosecurity measures to control spread could be impractical.
format Online
Article
Text
id pubmed-9708389
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-97083892022-12-02 Nasal transmission of equine parvovirus hepatitis Tomlinson, Joy E. Van de Walle, Gerlinde R. J Vet Intern Med EQUID BACKGROUND: Equine parvovirus hepatitis (EqPV‐H) is highly prevalent and causes subclinical to fatal hepatitis, which can occur in outbreaks. Whereas iatrogenic transmission is well documented, the mode of horizontal transmission is not known. The virus is shed in nasal, oral and fecal secretions, and PO transmission has been reported in a single horse. HYPOTHESIS/OBJECTIVE: Investigate the efficiency of PO and nasal transmission of EqPV‐H in a larger cohort. METHODS: Prospective experimental transmission study. Eleven EqPV‐H‐negative horses were inoculated with 5 × 10(6) genome equivalents EqPV‐H. Serum PCR and serology for EqPV‐H were performed weekly and monthly, respectively. Horses first were inoculated PO, and then intranasally 8 weeks later. RESULTS: No horse became viremic or seroconverted within 8 weeks after PO inoculation. After intranasal inoculation, 5 horses became viremic within 6 to 12 weeks and seroconverted within 10 to 19 weeks. After a period without monitoring from 12 to 19 weeks postinoculation, another 5 horses were found to be viremic at 19 to 22 weeks. The second set of 5 horses could have been infected by horizontal transmission from the first 5 because of cohousing. CONCLUSIONS AND CLINICAL IMPORTANCE: We demonstrated that EqPV‐H can be transmitted nasally. The prolonged eclipse phase before detectable viremia indicates biosecurity measures to control spread could be impractical. John Wiley & Sons, Inc. 2022-10-17 2022 /pmc/articles/PMC9708389/ /pubmed/36250682 http://dx.doi.org/10.1111/jvim.16569 Text en © 2022 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC. on behalf of the American College of Veterinary Internal Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle EQUID
Tomlinson, Joy E.
Van de Walle, Gerlinde R.
Nasal transmission of equine parvovirus hepatitis
title Nasal transmission of equine parvovirus hepatitis
title_full Nasal transmission of equine parvovirus hepatitis
title_fullStr Nasal transmission of equine parvovirus hepatitis
title_full_unstemmed Nasal transmission of equine parvovirus hepatitis
title_short Nasal transmission of equine parvovirus hepatitis
title_sort nasal transmission of equine parvovirus hepatitis
topic EQUID
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708389/
https://www.ncbi.nlm.nih.gov/pubmed/36250682
http://dx.doi.org/10.1111/jvim.16569
work_keys_str_mv AT tomlinsonjoye nasaltransmissionofequineparvovirushepatitis
AT vandewallegerlinder nasaltransmissionofequineparvovirushepatitis